Celcuity, Inc.는 세포 분석 회사로 활동한다. 이 회사는 새로운 암 하위 유형을 발견하고, 표적 치료로 치료받는 암 환자의 임상적 결과를 개선하도록 설계된 ...
예상 EPS $-1.41 · 매출 $4.26M · 2 명의 애널리스트
예상 EPS $-1.04 · 매출 $34.50M · 2 명의 애널리스트
예상 EPS $-4.85 · 매출 $38.21M · 5 명의 애널리스트
예상 EPS $-0.99 · 매출 $44.55M · 1 명의 애널리스트
EPS $-0.86 · 매출 $0.00
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $0 | — | — |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-177.0M | -58.4% | -49.2% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | — | — | — |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | — | — | — |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | — | — | — |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-153.5M | -83.4% | -0.3% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | — | — | — |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 194.3% | +129.3% | -1715.3% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 10.55x | +36.8% | -27.5% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $466.6M | +90.3% | +101.9% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -3.78 vs -3.85 | +1.9% | -1.44 vs -1.16 | -23.7% |
| 매출 서프라이즈 | $0 vs $1.2M | -100.0% | $0 vs $3.9M | -100.0% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Laing Lance G. | director, officer: Chief Science Officer | Common Stock | A | 20,000 | — |
| Aug 14, 2026 | Laing Lance G. | director, officer: Chief Science Officer | Performance Stock Units | A | 10,000 | — |
| Aug 14, 2026 | Sullivan Brian F. | director, officer: Chief Executive Officer | Common Stock | A | 80,000 | — |
| Aug 14, 2026 | Sullivan Brian F. | director, officer: Chief Executive Officer | Performance Stock Units | A | 120,000 | — |
| Aug 14, 2026 | Hahne Vicky | officer: Chief Financial Officer | Common Stock | A | 16,000 | — |
Operator: Good afternoon, ladies and gentlemen. Welcome to Security second Quarter 26 Financial Results Conference Call and Webcast. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. I would now like to turn the conference over to Jodi Sievers, corporate communications and investor relations at Celcuity. Please go ahead. Jodi Sievers: Thank you, Ludi, and good afternoon to everyone. Thank you for joining us today to read Celcuity's second quarter 26 financial results and business update. Earlier today, Cellcuity released financial results for the quarter ended 06/30/2026. The press release can be found on the Investors section of Celcuity's website Joining me on the call today are Brian F. Sullivan, Celcuity's Chief executive officer and cofounder Vicky Hahne, chief financial officer as well as Igor Gorbachevsky, chief medical officer; and Eldon C. Mayer, chief commercial officer, who will be available during Q&A. As we begin, I would like to remind listeners that our comments today will include some forward looking statements. These statements involve a number of risks and uncertainties which are outlined in today's press release and in our reports and filings with the SEC. Actual events and results may differ materially from those projected in the forward looking statements. Such forward looking statements and their implications involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. On this call, we will also refer to non GAAP financial measures. These non GAAP financial measures are used by management to make strategic decisions forecast future results, evaluate the company's current performance. Management believes the presentation of these non GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table reconciling the non GAAP financial measures to the GAAP measures in today's press release and with the And with that, I would like to turn the call over to Brian F. Sullivan, CEO of Cellcuity. Operator: Please go ahead, Brian. Brian F. Sullivan: Thank you, Jodi, and good afternoon, everyone. Thank you for joining our second quarter 26 operating and financial update conference call. Celcuity continues to make monumental progress. Advancing clinical development of gedatolisib for patients with HR positive, HER 2 negative advanced breast cancer. With the FDA approval of Revtopik, positive results from the PIK3CA mutant cohort of our pivotal VIKTORIA-1 study, and a preferred category 1 recommendation in the NCCN guidelines. We are well positioned to address a significant unmet need for the tens of thousands of patients each year by HR positive, HER 2 negative advanced …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer | USD 945,218 | Male | 1962 | Active |
Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director | USD 673,781 | — | 1962 | Active |
Vicky Hahne | Chief Financial Officer | USD 598,079 | Female | 1966 | Active |
Igor Gorbatchevsky | Chief Medical Officer | — | Male | — | Active |
Eldon C. Mayer | Chief Commercial Officer | — | Male | 1961 | Active |
Jodi Sievers | Head of Investor Relations & Corporate Communications | — | Female | — | Active |
Sheri Smith | Acting Head of Clinical Operations | — | Female | — | Active |
Brent Eilefson | General Counsel | — | Male | — | Active |
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy.
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,621 shares of the company's stock, valued at approximately $693,000. Several other hedge funds have also
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting rapid physician adoption and a potential blockbuster franchise.
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.
